Cargando…

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel

The impact of topical antiretrovirals for pre-exposure prophylaxis on humoral responses following HIV infection is unknown. Using a binding antibody multiplex assay, we investigated HIV-specific IgG and IgA responses to envelope glycoproteins, p24 Gag and p66 in the genital tract and plasma followin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archary, D, Seaton, KE, Passmore, JS, Werner, L, Deal, A, Dunphy, LJ, Arnold, KB, Yates, NL, Lauffenburger, DA, Bergin, P, Liebenberg, LJ, Samsunder, N, Mureithi, MW, Altfeld, M, Garrett, N, Karim, Q Abdool, Karim, SS Abdool, Morris, L, Tomaras, GD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848129/ https://www.ncbi.nlm.nih.gov/pubmed/26813340 http://dx.doi.org/10.1038/mi.2015.145

Ejemplares similares

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
por: McKinnon, Lyle R., et al.
Publicado: (2018)

Genital—Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women
por: Liebenberg, Lenine J. P., et al.
Publicado: (2017)

HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition
por: Liebenberg, Lenine J. P., et al.
Publicado: (2019)

Higher mucosal antibody concentrations in women with genital tract inflammation
por: Sobia, Parveen, et al.
Publicado: (2021)

Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage
por: Archary, Derseree, et al.
Publicado: (2015)

The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract
por: Jewanraj, Janine, et al.
Publicado: (2020)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists
por: Shey, Muki S., et al.
Publicado: (2016)

Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection
por: Jewanraj, Janine, et al.
Publicado: (2021)

Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012)

Diminished HIV Infection of Target CD4+ T Cells in a Toll-Like Receptor 4 Stimulated in vitro Model
por: Cromarty, Ross, et al.
Publicado: (2019)

Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model
por: Cromarty, Ross, et al.
Publicado: (2021)

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial
por: Succop, Stacey M., et al.
Publicado: (2014)

The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women
por: Abdool Karim, Salim S, et al.
Publicado: (2019)

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide
por: Ngandu, Nobubelo K., et al.
Publicado: (2017)

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial
por: Mansoor, Leila E, et al.
Publicado: (2014)

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
por: Karim, Quarraisha Abdool, et al.
Publicado: (2011)

CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
por: Gengiah, Tanuja Narayansamy, et al.
Publicado: (2022)

Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis
por: Mtshali, Andile, et al.
Publicado: (2021)

Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection
por: Naranbhai, Vivek, et al.
Publicado: (2013)

Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study
por: MacQueen, Kathleen M., et al.
Publicado: (2014)

HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services
por: Kharsany, Ayesha BM, et al.
Publicado: (2012)

Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women
por: Joag, Vineet, et al.
Publicado: (2018)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
por: Baxter, Cheryl, et al.
Publicado: (2019)

Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa
por: MacQueen, Kathleen M., et al.
Publicado: (2016)

Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
por: Baxter, Cheryl, et al.
Publicado: (2021)

Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression
por: Ngcobo, Samukelisiwe, et al.
Publicado: (2022)

Prospective study of oral pre‐exposure prophylaxis initiation and adherence among young women in KwaZulu‐Natal, South Africa
por: Mansoor, Leila E., et al.
Publicado: (2022)

No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
por: Chopera, Denis R., et al.
Publicado: (2013)

Current status of the HIV epidemic & challenges in prevention
por: Karim, Quarraisha Abdool
Publicado: (2017)

COVID-19 vaccine affordability and accessibility
por: Karim, Safura Abdool
Publicado: (2020)

The South African Response to the Pandemic
por: Abdool Karim, Salim S.
Publicado: (2020)

Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
por: Karim, Salim S Abdool
Publicado: (2021)

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
por: Mahomed, Sharana, et al.
Publicado: (2020)

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
por: Matthews, Lynn T., et al.
Publicado: (2013)

Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa( )
por: Samsunder, Natasha, et al.
Publicado: (2022)

Mechanisms of sexually transmitted infection‐induced inflammation in women: implications for HIV risk
por: Mwatelah, Ruth, et al.
Publicado: (2019)

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
por: Mahomed, Sharana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0fj3kk4edcbtij1s540vv23ch3